ABSTRACT: Metastatic melanoma is difficult to treat and is resistant to most current therapies. We hypothesized that stem cell related pathways may play a role in melanoma growth since stem cells and cancer cells share essential properties. Lately, the ABC transporter, ABCB5, as well as Cripto-1, CD20, CD133 and ABCG2 were used to isolate tumorigenic cells. Melanoma cells expressing MDR1 (ABCB1) were found in our lab to be enriched with ABCB5, Nanog, and Oct3/4 expression and were characterized by increased self-renewal capacity and anchorage independence. Melanoma significant heterogeneity was further demonstrated by Quintana et al. who found high prevalence of melanoma initiating cells when implanted into severely immunocompromised mice. Therefore, we took a more general approach in order to unravel pathways that are important for self-renewal and tumorigenicity of melanoma. We enriched for melanoma precursor cells (MPC) using culture conditions shown to enrich for normal melanocyte precursors. MPCs expressed higher levels of nanog and Oct3/4, as well as ABCB1 (MDR1) and ABCB5. Microarray analysis revealed deregulation of genes related to development, invasion, and cell cycle, in addition to upregulation of genes involved in Wnt signaling such as DVL3, DKK1, ID3, JAG1 and Wnt receptor, FZD7. We focused on Wnt signaling and found enrichment of FZD7+ cells in MPCs. Furthermore, FZD7+ cells co-expressed MDR1 and were enriched in highly tumorigenic xenograft parts when tested in mice. Inhibition of the Wnt pathway using secreted frizzled related protein-1 (sFRP1), resulted in attenuation of melanoma proliferation in a dose dependent manner demonstrating the important role of the Wnt pathway in melanoma growth and suggesting this pathway as a target for rational therapy. The canonical Wnt/beta-catenin pathway was not activated in MPC, as revealed using the Tcf Reporter assay. In contrast, we found increased of phosphorylated CAMKII, suggesting activation of the non-canonical Wnt pathway. Our data indicate that precursors within the melanoma tumor may acquire increased survival abilities that should be therapeutically targeted. In particular, we found that the non canonical wnt pathway and the wnt receptor FZD7 play a role in melanoma proliferation and tumorigenicity. We used specialized culture conditions that were found to enrich for normal melanoblasts, the precursors of melanocytes [7]. We found previously that these conditions result in a typical dedifferentiated unpigmented phenotype of melanoma cells in addition to enrichment of self-renewing cells [2]. Further characterization of these precursor cultures prepared from 6 human metastatic melanoma lesions revealed increased expression of stemness genes such as nanog and Oct3/4, as well as two recently reported melanoma precursor markers, MDR1 and ABCB5. Consistent with the normal melanoblast cultures we found increased expression of the melanoblast marker POU3F2 (BRN2, DCT). In contrast, the expression of MITF, a melanocyte differentiation marker was reduced by 85% in MPCs when compared with the primary culture (Figure 1a, relative expression of MPC vs. cells obtained from the same patient and cultured in regular conditions). Cell cycle analysis excluded death of differentiated cells as the cause of the precursor enrichment, as no apoptosis was evident (Figure 1b, c). Interestingly, there was an increase in S phase cells, indicating that these cells are undergoing divisions. Similarly, Wang et al. reported that CD133+ glioma cells have higher percentage of S phase cells as compared to CD133- cells [8]. We concluded that these culture conditions cause dedifferentiation of melanocytes in addition to enrichment by increased divisions of melanoma precursor cells. Therefore, we defined these cells as melanoma precursor cells (MPC).
